369 related articles for article (PubMed ID: 12010078)
21. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
Sharma P; Johnson DA; Monyak JT; Illueca M
Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
[TBL] [Abstract][Full Text] [Related]
22. Lansoprazole: a proton pump inhibitor.
Garnett WR
Ann Pharmacother; 1996 Dec; 30(12):1425-36. PubMed ID: 8968456
[TBL] [Abstract][Full Text] [Related]
23. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.
Spencer CM; Faulds D
Drugs; 1994 Sep; 48(3):404-30. PubMed ID: 7527761
[TBL] [Abstract][Full Text] [Related]
24. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.
Lauritsen K; Devière J; Bigard MA; Bayerdörffer E; Mózsik G; Murray F; Kristjánsdóttir S; Savarino V; Vetvik K; De Freitas D; Orive V; Rodrigo L; Fried M; Morris J; Schneider H; Eklund S; Larkö A;
Aliment Pharmacol Ther; 2003 Feb; 17(3):333-41. PubMed ID: 12562445
[TBL] [Abstract][Full Text] [Related]
25. Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis.
Kovacs TO; Lee CQ; Chiu YL; Pilmer BL; Metz DC
Aliment Pharmacol Ther; 2004 Oct; 20(8):883-9. PubMed ID: 15479360
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
Huang JQ; Hunt RH
Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
[TBL] [Abstract][Full Text] [Related]
27. Lansoprazole in the treatment of reflux oesophagitis: a survey of clinical studies.
Berstad A; Hatlebakk JG
Aliment Pharmacol Ther; 1993; 7 Suppl 1():34-6, discussion 61-6. PubMed ID: 8490077
[TBL] [Abstract][Full Text] [Related]
28. Long-term maintenance treatment with omeprazole in children with healed erosive oesophagitis: a prospective study.
Hassall E; Shepherd R; Koletzko S; Radke M; Henderson C; Lundborg P
Aliment Pharmacol Ther; 2012 Feb; 35(3):368-79. PubMed ID: 22176465
[TBL] [Abstract][Full Text] [Related]
29. Lansoprazole: a comprehensive review.
Zimmermann AE; Katona BG
Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
[TBL] [Abstract][Full Text] [Related]
30. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
Cheer SM; Prakash A; Faulds D; Lamb HM
Drugs; 2003; 63(1):101-33. PubMed ID: 12487624
[TBL] [Abstract][Full Text] [Related]
31. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview.
Chiba N
Can J Gastroenterol; 1997 Sep; 11 Suppl B():66B-73B. PubMed ID: 9347181
[TBL] [Abstract][Full Text] [Related]
32. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Robinson M; McFarland M; Sabesin S; Lehman GA; Castell D
Am J Gastroenterol; 1997 Mar; 92(3):429-37. PubMed ID: 9068463
[TBL] [Abstract][Full Text] [Related]
33. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis.
Gough AL; Long RG; Cooper BT; Fosters CS; Garrett AD; Langworthy CH
Aliment Pharmacol Ther; 1996 Aug; 10(4):529-39. PubMed ID: 8853756
[TBL] [Abstract][Full Text] [Related]
34. Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients.
Richter JE; Kahrilas PJ; Sontag SJ; Kovacs TO; Huang B; Pencyla JL
Am J Gastroenterol; 2001 Nov; 96(11):3089-98. PubMed ID: 11721754
[TBL] [Abstract][Full Text] [Related]
35. Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents.
Croom KF; Scott LJ
Drugs; 2005; 65(15):2129-35; discussion 2136-7. PubMed ID: 16225368
[TBL] [Abstract][Full Text] [Related]
36. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.
Lauritsen K; Devière J; Bigard MA; Bayerdörffer E; Mózsik G; Murray F; Kristjánsdóttir S; Savarino V; Vetvik K; De Freitas D; Orive V; Rodrigo L; Fried M; Morris J; Schneider H; Eklund S; Larkö A
Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():24; discussion 25-7. PubMed ID: 12614304
[TBL] [Abstract][Full Text] [Related]
37. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study.
Labenz J; Armstrong D; Lauritsen K; Katelaris P; Schmidt S; Schütze K; Wallner G; Juergens H; Preiksaitis H; Keeling N; Nauclér E; Adler J; Eklund S
Aliment Pharmacol Ther; 2005 Nov; 22(9):803-11. PubMed ID: 16225489
[TBL] [Abstract][Full Text] [Related]
38. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
Caos A; Breiter J; Perdomo C; Barth J
Aliment Pharmacol Ther; 2005 Aug; 22(3):193-202. PubMed ID: 16091056
[TBL] [Abstract][Full Text] [Related]
39. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group.
Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Haber M
Am J Gastroenterol; 1996 Sep; 91(9):1758-65. PubMed ID: 8792694
[TBL] [Abstract][Full Text] [Related]
40. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis.
Richter JE; Kovacs TO; Greski-Rose PA; Huang section sign B; Fisher R
Aliment Pharmacol Ther; 1999 Jun; 13(6):795-804. PubMed ID: 10383510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
